Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer.

Autor:	Wang CY; Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL., Shao C; Merck & Co, Inc, Rahway, NJ., McDonald AC; Merck & Co, Inc, Rahway, NJ., Amonkar MM; Merck & Co, Inc, Rahway, NJ., Zhou W; Merck & Co, Inc, Rahway, NJ., Bortnichak EA; Merck & Co, Inc, Rahway, NJ., Liu X; Merck & Co, Inc, Rahway, NJ.
Jazyk:	angličtina
Zdroj:	JCO clinical cancer informatics [JCO Clin Cancer Inform] 2023 Jul; Vol. 7, pp. e2200184.
DOI:	10.1200/CCI.22.00184
Abstrakt:	Purpose: Evaluating whether patient populations in clinico-genomic oncology databases are comparable with whom in other databases without genomic component is important. Methods: Four databases were compared for colorectal cancer (CRC) cases and stage IV CRC cases: American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE-BPC), The Cancer Genome Atlas (TCGA), SEER-Medicare, and MarketScan Commercial and Medicare Supplemental claims databases. These databases were also compared with the SEER registry database which serves as national benchmarks. Demographics, clinical characteristics, and overall survival were compared in patients with newly diagnosed CRC and patients with stage IV CRC across databases. Treatment patterns were further compared in patients with stage IV CRC. Results: A total of 65,976 patients with CRC and 13,985 patients with stage IV CRC were identified. GENIE-BPC had the youngest patient population (mean age [years]: CRC, 54.1; stage IV CRC, 52.7). SEER-Medicare had the oldest patient population (CRC, 77.7; stage IV CRC, 77.3). Most patients were male and of White race across databases. GENIE-BPC had the highest proportion of patients with stage IV CRC (48.4% v other databases 13.8%-25.4%) and patients receiving treatments (95.7% v 37.6%-59.1%). Infusional fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab was the most common regimen across databases accounting for 47.3%-78.5% of patients receiving first line of therapy. The median survival from diagnosis was 36, 94, 44 months (CRC) and 23, 36, 15 months (stage IV CRC) for patients in GENIE-BPC after left truncation, TCGA, and SEER-Medicare databases, respectively. Conclusion: Compared with other databases, GENIE-BPC had the youngest patients with CRC with the most advanced disease and the largest proportion of patients receiving treatment. Investigators should consider adjustments when extrapolating results from clinico-genomic databases to the general CRC population.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu